Crystal form of deuterated AZD9291, preparation method and application

By developing the methanesulfonate crystal form of deuterated AZD9291, the problem of resistance to existing EGFR inhibitors in patients with EGFR T790M mutant lung cancer was solved, the solubility and bioavailability of the compounds were improved, and better treatment was achieved Effect.

CN118894841APending Publication Date: 2024-11-05TYK MEDICINES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410940416.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2017-05-24
Filing Date
2018-05-22
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

Existing EGFR inhibitors are highly resistant to patients with EGFR T790M mutant lung cancer, resulting in reduced therapeutic effects and lack of effective drug solutions.

Method used

A stable crystal form of deuterated AZD9291 was developed, and its X-ray powder diffraction peak was determined by Cu-Kα ray measurement, and the preparation method in the form of methanesulfonate was used to improve the solubility and bioavailability of the compound.

Benefits of technology

Increased the blood drug concentration and brain concentration of deuterated AZD9291 in the body, enhanced the inhibitory activity of drug-resistant EGFR T790M mutant lung cancer, achieved better efficacy and bioavailability, and the physicochemical properties of the crystal form are stable. , meets the development requirements of API and CMC.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118894841A_ABST
    Figure CN118894841A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of medicines, and particularly discloses a crystal form of deuterated AZD9291 as well as a preparation method and application of the crystal form. The crystal form of the deuterated AZD9291 has diffraction peaks when the 2 theta angle is 7.1 + / -0.2, 8.5 + / -0.2, 9.4 + / -0.2, 10.3 + / -0.2, 15.1 + / -0.2, 16.3 + / -0.2, 18.7 + / -0.2, 22.0 + / -0.2, 25.6 + / -0.2 and 26.0 + / -0.2 through X-ray powder diffraction obtained through Cu-K alpha ray measurement. The invention also discloses an application of the crystal form of the deuterated AZD9291 in preparation of a medicine for treating cancers. The deuterated AZD9291 crystal form provided by the invention is stable in physicochemical property and good in metabolic stability, the in-vivo blood concentration and the brain concentration of the deuterated AZD9291 crystal form are remarkably improved, and a better curative effect can be achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a deuterated AZD9291 crystal form, a preparation method and application of the crystal form, and belongs to the technical field of medicine. Background Art

[0002] Epidermal Growth Factor Receptor EGFR (Epidermal Growth Factor Receptor) is a transmembrane protein tyrosine kinase of the erbB receptor family. When bound to a growth factor ligand (e.g., epidermal growth factor (EGF)), the receptor can homodimerize with an attached EGFR molecule, or heterodimerize with another family member (e.g., erbB2 (HER2), erbB3 (HER3), or erbB4 (HER4)). Homodimerization and / or heterodimerization of erbB receptors lead to phosphorylation of key tyrosine residues in the intracellular domain, and lead to stimulation of many intracellular signal transduction pathways involved in cell proliferation and survival. Disregulation of erbB family signal transduction promotes proliferation, invasion, metastasis, angiogenesis, and tumor cell survival, and has been described in many human cancers (including lung cancer, head and neck cancer, and breast cancer, etc.).

[0003] Therefore, the erbB family is a reasonable target for the development of anticancer drugs, such as many drugs targeting EGFR or erbB2, which are now widely used in clinical practice, including gefitinib (IRESSA TM ), erlotinib (TARCEVA TM ) and lapatinib (TYKERB TM ) etc. New England Journal of Medicine (2008) (No. 358, 1160-1174) and Biochemical and Biophysical Research Communications (2004) (No. 319, 1-11) both provide detailed discussions on erbB receptor signaling and its involvement in tumorigenesis.

[0004] Lung cancer is the cancer with the highest incidence rate in the world. In China, the incidence rate of lung cancer ranks first among all cancers, and it is also the cancer with the highest incidence and mortality rate in China. Among lung cancer patients in China, about 30% of patients have EGFR mutations, of which L858R and exon 19 deletion mutations account for about more than 90%. Such patients are more sensitive to EGFR inhibitors. The first-generation EGFR inhibitors currently on the market, such as erlotinib and gefitinib, have good therapeutic effects on such patients, which can shrink tumors in more than 60% of patients and significantly prolong the progression-free survival of patients. However, the vast majority of patients will acquire drug resistance in 6-12 months. This drug resistance pattern is a further mutation of EGFR, which reduces its sensitivity to the first-generation EGFR inhibitors. The most common of these mutations is the so-called "gatekeeper" mutation T790M (Science, 2004, Vol. 304, 1497-1500; New England Journal of Medicine 2004, 350, 2129-2139). The original L-threonine (T) at this site is replaced by L-methionine (M). The mutated EGF tyrosine kinase R no longer binds to gefitinib and erlotinib, so that the first-generation EGFR inhibitors will no longer work, resulting in this type of patients currently being in a state where there is no drug available. Clinically, 50% of patients who are resistant to the first-generation EGFR inhibitors have EGFR T790M mutations. In the T790M mutant cell line H1975, the first-generation EGFR inhibitors, such as gefitinib and erlotinib, are greater than 3μM and are basically inactive.

[0005] In order to improve the inhibitory activity against drug-resistant EGFR T790M and other mutations, WO2013014448 discloses pyrimidine derivatives that can be used as EGFR inhibitors and their use in treating cancer, wherein G is selected from 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl, 1H-indol-3-yl, 1-methyl-1H-indol-3-yl or pyrazolo[1,5-a]pyridin-3-yl, and R 2 It is methyl or methoxy, and the structure is as follows:

[0006]

[0007] In the patent disclosure document, the compound (AZD9291) as shown in Formula III was approved by the U.S. FDA on November 13, 2015 (trade name: Tagrisso, AZD9291) for marketing, and is used to treat patients with advanced non-small cell lung cancer who are positive for the epidermal growth factor receptor EGFR T790M mutation.

[0008]

[0009] At present, CN104140418B and CN105237515A etc. have reported some deuterated AZD9291 compounds, but there is no report on the crystal form patent of the pharmaceutically acceptable salt of deuterated AZD9291. Crystal form is the solid state of the drug. The study of drug crystal form is the study of the basic state of the drug. Only when the chemical drug crystal form state has a relatively full and comprehensive understanding, it is possible to find a drug crystal form solid material that is more suitable for treating diseases. Drug crystal form can affect the physicochemical properties of the drug, directly affecting the basis of the clinical treatment of the disease. At the same time, due to the solubility of some drugs themselves and other problems, it is made into a salt that can be accepted for pharmaceutical use, which can greatly improve its solubility and improve the absorption and utilization of the drug. Our company has been engaged in the research of lung cancer drugs. We have started the research of EGFR target drugs very early and have achieved a series of research results, such as patents CN102659692, US08916572, CN107382879, WO2017219500 and WO2018050052, etc. In our research process, we found that the compound shown in formula III can enter the brain through the blood-brain barrier, and this result is also reported in the document Clin. Cancer Res. 2016, 22 (20), 5130-5140. However, when the compound shown in formula III is metabolized in the body and the methyl group on the indole nitrogen is removed, the compound shown in formula IV (AZ5104) cannot pass through the blood-brain barrier, so it loses its effect on tumors metastasized to the brain. If the methyl group on the indole nitrogen of the compound shown in formula III is deuterated, the metabolic stability of the methyl group is increased, and its blood drug concentration and brain concentration in the body are better improved, thereby achieving better therapeutic effects. Therefore, it is of great significance to study the stable crystal form of deuterated AZD9291.

[0010] Summary of the invention

[0011] The present invention mainly provides a crystal form of deuterated AZD9291, and provides a preparation method and pharmaceutical use thereof.

[0012] The present invention provides a deuterated AZD9291 crystal form, the structural formula of which is shown in formula (I) or formula (II).

[0013]

[0014] The X-ray powder diffraction of this crystal form measured using Cu-Kα rays has diffraction peaks at 2θ angles (the unit of 2θ angle is °): 7.1±0.2, 8.5±0.2, 9.4±0.2, 10.3±0.2, 15.1±0.2, 16.3±0.2, 18.7±0.2, 22.0±0.2, 25.6±0.2, and 26.0±0.2.

[0015] The present invention provides a deuterated AZD9291 crystal form, the structural formula of which is shown in formula (I) or formula (II), and the X-ray powder diffraction of the crystal form measured by Cu-Kα ray at 2θ angle (unit: °) is: 7.1±0.2, 8.5±0.2, 9.4±0.2, 10.3±0.2, 15.1±0.2, 16.3±0.2, 17.0±0.2, 17. There are diffraction peaks at 3±0.2, 17.7±0.2, 18.7±0.2, 19.4±0.2, 19.7±0.2, 20.2±0.2, 20.7±0.2, 21.6±0.2, 22.0±0.2, 22.8±0.2, 23.5±0.2, 24.2±0.2, 24.8±0.2, 25.6±0.2, and 26.0±0.2.

[0016] The present invention provides a deuterated AZD9291 crystal form, the structural formula of which is shown in formula (I) or formula (II), and the X-ray powder diffraction of the crystal form measured by Cu-Kα ray at a 2θ angle (the unit of 2θ angle is °) is: 7.1±0.2, 8.5±0.2, 9.4±0.2, 10.3±0.2, 12.6±0.2, 14.4±0.2, 15.1±0.2, 15.6±0.2, 16.3±0.2, 17.0±0.2, 17.3±0.2, 17.7±0.2, 18.2±0.2, 18.7±0.2, 19.4±0.2, 19.7±0.2, 2 There are diffraction peaks at 0.2±0.2, 20.7±0.2, 21.6±0.2, 22.0±0.2, 22.8±0.2, 23.5±0.2, 24.2±0.2, 24.8±0.2, 25.6±0.2, 26.0±0.2, 26.9±0.2, 27.7±0.2, 28.2±0.2, 29.5±0.2, 30.7±0.2, 31.7±0.2, 32.5±0.2, 33.1±0.2, 33.8±0.2, 34.6±0.2, 34.9±0.2, 35.6±0.2, 37.9±0.2, and 38.7±0.2.

[0017] The present invention provides a deuterated AZD9291 crystal form, the structural formula of which is shown in formula (I) or formula (II), and the X-ray powder diffraction pattern of the crystal form measured using Cu-Kα radiation is substantially as follows: Figure 1 shown.

[0018] The present invention also provides use of the deuterated AZD9291 crystal form in preparing a drug for treating cancer.

[0019] Preferably, the cancer is non-small cell lung cancer.

[0020] The method for preparing the crystalline form of deuterated AZD9291 provided by the present invention comprises the following steps:

[0021] 1) adding a deuterated AZD9291 compound to a solvent system, heating to 40-80° C., then adding methanesulfonic acid to the solvent system, wherein the molar number of methanesulfonic acid is 1-1.5 times that of the deuterated AZD9291 compound, maintaining the temperature at 40-80° C., reacting for 1-5 hours, and then filtering under hot conditions;

[0022] 2) cooling the filtrate after hot filtration naturally at room temperature to precipitate crystals;

[0023] 3) filtering and collecting the crystals, and then washing and drying the crystals to obtain the crystalline form of deuterated AZD9291 mesylate.

[0024] As a specific embodiment, the solvent system is any one of methanol, ethanol, isopropanol, acetone, acetonitrile, tetrahydrofuran, water, 1,4-dioxane, tert-butyl acetate, acetone / water mixture, ethanol / tert-butyl acetate mixture, and 1,4-dioxane / water mixture.

[0025] As an optimized implementation, the solvent system is acetonitrile or an acetone / water mixture.

[0026] As an optimized implementation manner, the volume ratio of acetone to water in the acetone / water mixture is: acetone / water = 10:1 to 15:1.

[0027] The beneficial effects of the present invention are as follows: the crystalline form of deuterated AZD9291 mesylate provided by the present invention has stable physical and chemical properties and a stable deuteration rate, which ensures the deuteration rate of the deuterated methyl group on the indole nitrogen, so that it has good metabolic stability in the body and has good bioavailability in the body. For example, in a rat experiment, the oral bioavailability is 30.9%. At the same time, in a rat PO (oral) pharmacokinetic experiment, the body has a good blood drug concentration and brain concentration distribution, the highest blood drug concentration can reach 117 ng / mL, and the AUC can reach 1268 h·ng / mL, thereby achieving a better therapeutic effect. Moreover, the single impurity is below 0.1%, which is very consistent with the development of API and CMC. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 The X-ray powder diffraction pattern of the deuterated AZD9291 mesylate crystalline form provided by the present invention;

[0029] Figure 2 The X-ray powder diffraction pattern of the deuterated AZD9291 mesylate salt crystal provided by the present invention after a 6-month accelerated stability test;

[0030] Figure 3 It is the DSC-TGA spectrum of the deuterated AZD9291 mesylate crystalline form provided by the present invention;

[0031] Figure 4 It is a liquid phase spectrum of the deuterated AZD9291 mesylate crystal provided by the present invention. DETAILED DESCRIPTION

[0032] The technical solution of the present invention is described in detail below.

[0033] Preparation of the crystalline form of the compound represented by formula (I) or formula (II)

[0034]

[0035] 1) Synthesis of deuterated AZD9291 (D-AZD9291)

[0036] The synthetic route is as follows:

[0037]

[0038] Dissolve 50 mg of intermediate B, 130 mg of intermediate A and 35 mg of p-toluenesulfonic acid monohydrate in 5 ml of 2-pentanol, then heat to 50 degrees Celsius, stir overnight under nitrogen protection, TLC shows that the raw material has basically disappeared, the reaction solution is dried by rotation, and then 20 ml of dichloromethane and 20 ml of saturated sodium carbonate aqueous solution are added. After separation, the water layer is washed twice with 20 ml of dichloromethane, the organic layers are combined, dried, and dried by rotation, and separated by column to obtain 50 mg of D-AZD9291 product. The nuclear magnetic analysis data of D-AZD9291 are as follows: 1 H-NMR (400MHz, d 6 -DMSO) δ10.22(s,1H),9.16(s,1H),8.68(s,1H),8.33(d,J=5.2Hz,1H),8.24(d,J= 8.0Hz,1H),7.90(s,1H),7.53(d,J=8.2Hz,1H),7.26-7.22(m,2H),7.17-7.13(m,1H ),7.04(s,1H),6.46-6.40(m,1H),6.30-6.25(m,1H),5.79-5.76(m,1H),3.86(s,3 H),2.90-2.37(m,2H),2.72(s,3H),2.30-2.27(m,2H),2.20(s,6H); m / z(ES+)(M+H) + =503.3.

[0039] 2) Preparation of a crystalline form of a compound represented by formula (I) or formula (II)

[0040]

[0041] Method 1: Add compound D-AZD9291 (5.02 g, 1 mmol) to acetonitrile (40 mL), then heat the solution to 70°C, add methanesulfonic acid (0.96 g, 1 mmol) in acetonitrile (10 mL) dropwise to the above solution. After the addition, stir the mixture at 70°C for 2 hours, filter it hot, and let the filtrate stand at room temperature for 10 hours to crystallize. Then filter it, collect the solid, wash it with acetonitrile, and then dry it in a vacuum drying oven at 40°C to obtain a crystalline form. 1 H-NMR (400MHz, d 6 -DMSO)δ9.54(s,1H),9.22(s,1H),8.78(s,1H),8.53(s,1H),8.33-8.30(m,2H ),7.94(s,1H),7.53(d,J=8.2Hz,1H),7.26-7.22(m,2H),7.17-7.13(m,1H),7 .01(s,1H),6.72-6.65(m,1H),6.36-6.31(m,1H),5.83-5.80(m,1H),3.89(s, 3H),3.30-3.21(m,4H),2.81(s,6H),2.62(s,3H),2.33(s,3H); m / z(ES+)(M+H) + =503.3.

[0042] Method 2: Compound D-AZD9291 (5.02 g, 1 mmol) was added to acetone (45 mL) and water (4.5 mL), and then the solution was heated to 50°C, and an acetone solution (10 mL) of methanesulfonic acid (0.96 g, 1 mmol) was added dropwise to the above solution. After the addition, the mixture was stirred at 50°C for 2 hours, hot filtered, and the filtrate was allowed to stand at room temperature for 10 hours for crystallization, and then filtered to collect the solid and wash it with a mixture of acetone and water (V 丙酮 / V 水 =10 / 1), and then dried in a vacuum drying oven at 40°C to obtain a crystalline form. 1 H-NMR (400MHz, d 6-DMSO)δ9.54(s,1H),9.22(s,1H),8.78(s,1H),8.53(s,1H),8.33-8.30(m,2H ),7.94(s,1H),7.53(d,J=8.2Hz,1H),7.26-7.22(m,2H),7.17-7.13(m,1H),7 .01(s,1H),6.72-6.65(m,1H),6.36-6.31(m,1H),5.83-5.80(m,1H),3.89(s, 3H),3.30-3.21(m,4H),2.81(s,6H),2.62(s,3H),2.33(s,3H); m / z(ES+)(M+H) + =503.3.

[0043] Among them, the synthesis route of intermediate A is as follows:

[0044]

[0045] Synthesis of compound 2: Under nitrogen protection, compound 1 (15 g, 128.2 mmol) and 260 mL of tetrahydrofuran were added to a 500 mL three-necked flask, then cooled to 0°C, sodium hydride (7.7 g, 192.0 mmol) was added in batches, and after the addition, the mixture was reacted at 0°C for 1 hour, and then deuterated iodomethane (27.8 g, 192.0 mmol) was added dropwise to the reaction solution, and the temperature of the reaction solution was kept at 0°C. After the addition of deuterated iodomethane, the mixture was slowly heated to room temperature and the reaction was continued for 10 hours. Ice water (200 mL) was added dropwise to the reaction mixture, and the reaction system was kept at 0°C. The mixture was extracted with ethyl acetate (100 mL × 3), the organic phases were mixed, dried, and passed through a column to obtain 15 g of mixture 2. m / z (ES+) (M+H) + =135.1.

[0046] Synthesis of intermediate A: Under nitrogen protection, compound 2 (15 g, 111.9 mmol), compound 3 (20.0 g, 134.3 mmol), ferric chloride (21.7 g, 134.3 mmol) and 150 mL of DME were added to a 250 mL three-necked flask, and then refluxed overnight. After the reaction was completed, the reaction system was cooled to room temperature and filtered. The filter cake was washed three times with 50 mL of methanol, and then the organic phase was spin-dried and passed through a column to obtain 13.1 g of intermediate A. 1 H-NMR (400MHz, d 6 -DMSO)δ7.35(2H,m),7.64(1H,dd),7.88(1H,d),8.45-8.52(1H,m),8.56(1H,s),8.62(1H,d); m / z(ES+)(M+H) +=247.1.

[0047] The synthesis route of intermediate B is as follows:

[0048]

[0049] Synthesis of B1-2: Weigh 50g of raw material B1-1, add 500ml of methanol to dissolve it completely, add 10g of Pd / C, and hydrogenate at 35°C for two days. Monitor with a plate, and when the raw material reaction is complete, treat it. Filter out Pd / C directly, spin dry the methanol phase to obtain 39g of crude product, and directly use it for the next step.

[0050] Synthesis of B1-3: Take 39g of raw material B1-2 and add it to 500ml of concentrated sulfuric acid under ice-salt bath. Control the temperature below 10℃ and stir to dissolve completely. Keep the temperature below 10℃ and add 1ep of potassium nitrate, stir overnight at room temperature. The next day, pour into ice water, adjust pH>7 with ammonia water, extract with ethyl acetate, dry, and pass through a column to obtain 44g of product. 1 H-NMR (CDCl 3 )δ7.39(d,J=7.2Hz,1H),6.63(d,J=12.4Hz,1H),3.94(s,3H),3.90(broad,2H).

[0051] Synthesis of B1-4: Take 20g of raw material B1-3, add it to 500ml of dichloromethane, and cool it to -5℃ in an ice-salt bath. Add 1.1eq of di-tert-butyl dicarbonate in dichloromethane dropwise, and after the dropwise addition, add 0.2eq of DMAP. Naturally warm it to room temperature and stir overnight. The next day, tap the plate, the reaction is complete, and pass through a column to obtain 24g of a yellow solid. 1 H-NMR (CDCl 3 )δ8.89(s,1H),6.97(s,1H),6.71(d,J=12.4Hz,1H),3.97(s,3H),1.53(s,9H); m / z(ES+)(M+H) + =285.0.

[0052] Synthesis of B1-5: Take 13.5g of raw material B1-4, add it into 200ml of DMA, and stir until it is completely dissolved. Then add 2eq of N,N,N'-trimethylethylenediamine and 3eq of DIEA, heat to 110℃ and stir overnight. The next day, the reaction is complete. After treatment, 22g of crude oil is obtained, which is directly used in the next step. 1 H-NMR (CDCl 3)δ8.54(s,1H),6.85(s,1H),6.60(s,1H),3.90(s,3H),3.22(t,J=6.8Hz,2H), 2.81(s,3H),2.55(t,J=7.2Hz,2H),2.26(s,6H),1.49(s,9H); m / z(ES+)(M+H) + =369.3.

[0053] Synthesis of B1-6: Take 22 g of raw material B1-5, add it to 400 ml of ethyl acetate, stir until it is completely dissolved, then add 4.07 g of Pd / C, and hydrogenate overnight at 20°C. The next day, the raw material reaction is complete, Pd / C is directly filtered off, and concentrated to obtain 17 g of crude product as black oil, which is directly used for the next step. 1 H-NMR (CDCl 3 )δ7.517(s,1H),6.941(s,1H),6.61(s,1H),4.10(m,2H),3.76(s,3H),2.92 (m,2H),2.62(s,3H),2.40(m,2H),2.27(s,6H),1.49(s,9H); m / z(ES+)(M+H) + =339.4.

[0054] Synthesis of B1-7: 17.3 g of raw material B1-6, add 500 ml of dichloromethane and 1.2 eq of DIEA, cool to -5°C in an ice-salt bath, and protect with argon. Add 1.1 eq of acryloyl chloride dropwise, and naturally warm to room temperature after the dropwise addition. After 3 hours, the reaction is complete. Directly evaporate and concentrate at low temperature to remove the solvent. Obtain about 23 g of crude product. Directly use for the next step.

[0055] Synthesis of intermediate B: 23g of raw material B1-7 was added to 50ml of THF and cooled to -5℃ in an ice-salt bath. 100ml of concentrated hydrochloric acid was added and the temperature was controlled below 10℃. After stirring for 2 hours, the reaction was completed. After treatment, the product was passed through a column to obtain 5.2g of product. 1 H-NMR (CDCl 3 )δ10.10(s,1H),7.97(s,1H),6.68(s,1H),6.41-6.21(m,2H),5.65(m,1H),3. 81(s,3H),3.76(s,2H),2.82(m,2H),2.65(s,3H),2.20(s,6H); m / z(ES+)(M+H) + =293.3.

[0056] The prepared crystalline form of the compound represented by formula (I) or formula (II) is subjected to X-ray powder diffraction analysis, and the obtained X-ray powder diffraction pattern is shown in Figure 1 The X-ray powder diffraction peak data are shown in Table 1. The X-ray powder diffraction patterns of the crystal forms obtained by Method 1 and Method 2 of the present invention are consistent.

[0057] Table 1

[0058]

[0059]

[0060] In Table 1, the 2θ angle values ​​of the X-ray powder diffraction peaks have an error range of ±0.2°. It should be understood that the 2θ values ​​of the X-ray powder diffraction pattern may vary slightly between machines and samples, and the numerical range may differ within ±0.2 units, so the quoted values ​​cannot be interpreted as absolute values.

[0061] Considering that the intensity of the peak represented by the 2θ angle varies, especially the intensity of some peaks is lower than 20% of the strongest peak, the accuracy of the data represented is greatly affected by the instrument conditions and may have large errors. Therefore, the peak with a peak intensity higher than 20% can be selected as the characteristic peak of the crystal form of the present invention.

[0062] The melting point of the prepared crystalline compound represented by formula (I) or formula (II) is 239-240°C (melting point tester test). DSC (differential scanning calorimetry) shows that the melting point is between 249°C and 254°C.

[0063] The stability of the crystal form of the compound represented by formula (I) or formula (II) was further tested using a drug accelerated stability test chamber; the accelerated test conditions were 40° C. and 75% relative humidity. The test results are shown in Table 2.

[0064] Table 2

[0065]

[0066]

[0067] After the crystal form of the compound represented by formula (I) or formula (II) has completed the six-month accelerated test in the drug accelerated stability test chamber, a sample is taken for X-ray powder diffraction analysis. The obtained X-ray powder diffraction pattern is shown in Figure 2 shown.

[0068] contrast Figure 1 and Figure 2 It can be concluded that Figure 1 and Figure 2 The graphs are consistent, and the 2θ angle values ​​are consistent within the error range of the instrument, indicating that the crystal form of the crystalline form of the present invention remains consistent after 6 months of accelerated testing.

[0069] The above experimental results indicate that the physicochemical properties of this crystal form are stable, and the deuteration rate can remain unchanged. This deuterated AZD9291 crystal form is very suitable for application in subsequent drug development such as formulations.

[0070] At the same time, we also conducted differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) studies on the deuterated AZD9291 mesylate crystalline form of the present invention. The results are as follows: Figure 3 As shown in the DSC-TGA diagram, it can be seen that the crystalline form of the present invention has very low residual solvent and high sample purity, and is very suitable for subsequent pharmaceutical research.

[0071] Furthermore, the deuterated AZD9291 mesylate crystal of the present invention was used in an oral bioavailability test on rats, and its oral bioavailability can reach 30.9%. The high oral bioavailability proves that the crystal is suitable for the development of oral preparations.

[0072] The crystal form of the compound represented by formula (I) or formula (II) obtained by method 1 or method 2 of the present invention was placed at room temperature for 1 month without any change in properties such as moisture absorption. At the same time, through accelerated experiments, it was found that its physical and chemical properties were also very stable. Through HPLC detection (HPLC spectrum see Figure 4 ), HPLC test data are shown in Table 3. Its purity is as high as 99.83%, and the content of each single impurity is less than 0.1%, which is very suitable for subsequent research and development of raw materials and preparations, as well as subsequent drug metabolism kinetics experiments and animal experiments.

[0073] Table 3

[0074]

[0075]

[0076] The deuterated AZD9291 mesylate crystalline form prepared by the present invention was placed open and flat in a laboratory at room temperature to investigate its stability at room temperature. The purity was tested by HPLC. The results are shown in Table 4.

[0077] It can be seen from the results in the table that the crystals prepared by the present invention have good stability at room temperature and the purity is consistent when detected by HPLC.

[0078] Table 4

[0079]

[0080] The deuterated AZD9291 crystal form provided by the present invention can be used as an epidermal growth factor receptor EGFR inhibitor, in particular an EGFR mutant inhibitor.

[0081] The deuterated AZD9291 crystal provided by the present invention can be used to prepare drugs for regulating EGFR tyrosine kinase activity or treating EGFR-related diseases, which inhibit one or more activation or resistance mutations of EGFR, such as L858R activation mutant, Exon19 deletion EGFR activation mutant, T790M resistance mutant, and is particularly suitable for cancer treatment, such as non-small cell lung cancer.

Claims

1. A crystalline form of deuterated AZD9291, characterized in that: The structural formula is shown in formula (I) or formula (II): The X-ray powder diffraction of this crystal form measured using Cu-Kα rays has diffraction peaks at 2θ angles (unit: °): 7.1±0.2, 8.5±0.2, 9.4±0.2, 10.3±0.2, 15.1±0.2, 16.3±0.2, 18.7±0.2, 22.0±0.2, 25.6±0.2, and 26.0±0.

2.

2. A crystalline form of deuterated AZD9291, characterized in that: The structural formula is shown in formula (I) or formula (II): The X-ray powder diffraction of this crystal form measured using Cu-Kα rays has diffraction peaks at 2θ angles (unit: °): 7.1±0.2, 8.5±0.2, 9.4±0.2, 10.3±0.2, 15.1±0.2, 16.3±0.2, 17.0±0.2, 17.3±0.2, 17.7±0.2, 18.7±0.2, 19.4±0.2, 19.7±0.2, 20.2±0.2, 20.7±0.2, 21.6±0.2, 22.0±0.2, 22.8±0.2, 23.5±0.2, 24.2±0.2, 24.8±0.2, 25.6±0.2, and 26.0±0.

2.

3. A crystalline form of deuterated AZD9291, characterized in that: The structural formula is shown in formula (I) or formula (II): The X-ray powder diffraction of the crystal form measured by Cu-Kα radiation at a 2θ angle (unit: °) is: 7.1±0.2, 8.5±0.2, 9.4±0.2, 10.3±0.2, 12.6±0.2, 14.4±0.2, 15.1±0.2, 15.6±0.2, 16.3±0.2, 17.0±0.2, 17.3±0.2, 17.7±0.2, 18.2±0.2, 18.7±0.2, 19.4±0.2, 19.7±0.2, 20.2±0.2, 20.7±0.2, 21.6 ±0.2, 22.0±0.2, 22.8±0.2, 23.5±0.2, 24.2±0.2, 24.8±0.2, 25.6±0.2, 26.0±0.2, 26.9±0.2, 27.7±0.2, 28.2±0.2, 29.5±0.2, 30.7±0.2, 31.7±0.2, 32.5±0.2, 33.1±0.2, 33.8±0.2, 34.6±0.2, 34.9±0.2, 35.6±0.2, 37.9±0.2, and 38.7±0.

2.

4. Use of the deuterated AZD9291 crystalline form according to any one of claims 1 to 3 in the preparation of a medicament for treating cancer.

5. Use of the deuterated crystalline form of AZD9291 according to claim 4, wherein the cancer is non-small cell lung cancer.

6. A method for preparing the crystalline form of deuterated AZD9291 as claimed in any one of claims 1 to 3, comprising the following steps: 1) adding a deuterated AZD9291 compound to a solvent system, heating to 40-80° C., then adding methanesulfonic acid to the solvent system, wherein the molar number of methanesulfonic acid is 1-1.5 times that of the deuterated AZD9291 compound, maintaining the temperature at 40-80° C., reacting for 1-5 hours, and then filtering under hot conditions; 2) cooling the filtrate after hot filtration naturally at room temperature to precipitate crystals; 3) filtering and collecting the crystals, and then washing and drying the crystals to obtain the crystalline form of deuterated AZD9291 mesylate.

7. The method for preparing the crystal form according to claim 6, wherein the solvent system is any one of methanol, ethanol, isopropanol, acetone, acetonitrile, tetrahydrofuran, water, 1,4-dioxane, tert-butyl acetate, acetone / water mixture, ethanol / tert-butyl acetate mixture, and 1,4-dioxane / water mixture.

8. The method for preparing the crystal form according to claim 7, wherein the solvent system is acetonitrile or an acetone / water mixture.

9. The method for preparing a crystal form according to claim 8, wherein the volume ratio of acetone to water in the acetone / water mixture is: acetone / water = 10:1 to 15:1.